The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAKR.L Regulatory News (AKR)

  • There is currently no data for AKR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

27 Oct 2008 07:00

RNS Number : 6246G
Akers Biosciences, Inc.
27 October 2008
 

Embargoed: 0700hrs, 27 October 2008 

Akers Biosciences Inc.

("ABI" or the "Company")

Directorate Change

Akers Biosciences, Inc (AIM: AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, is pleased to announce the appointment of Charles Bunker to its Board as a non-executive Director with immediate effect. 

Charles Spencer Bunker (57) is a Chartered Accountant with over 25 years of experience as a corporate financier. As a founding member of Kerburn Rose, an independent corporate finance house, he has made a significant contribution to the value enhancement of a number of businesses across a range of sectors. He is a former Chairman of the Board of Governors of the European Business School and of Regent's College, the UK based American college. He has a personal interest in the healthcare sector in which ABI is involved, having served as a non-executive Director of both a leading NHS Trust and Health Authority. 

Current directorships/partnerships:

Burnash LLP (Dormant) 

Ashgreen Hotels Limited

Ellax plc (Dormant) 

Kerburn Rose Capital Limited

Kerburn Rose LLP

Xella Limited (not trading)

JS Lister Limited -Eire

Beemount Properties Limited -Eire

Welding Products Limited -Eire

Zuvrida Company Limited -Eire

Simpatico Limited -Eire 

Previous directorships/partnerships:

Lion Capital Partners Limited

Charles Bunker was appointed a director of Lion Capital Partners Limited on 20 June 2005. At an extraordinary general meeting of shareholders, the board of directors resolved on 27 July 2005, that Bank of Scotland should appoint a receiver. The Statement of Affairs detailed an estimated shortfall to creditors of £139,000.

Charles Bunker was appointed a director of Drings of Bath plc ("Drings") on 28 June 1996 and resigned as a director on 11 June 1998An administrative receiver was appointed on 20 October 1998 and Drings was put into creditors' voluntary liquidation at which time there was an estimated shortfall to creditors of £840,000.

On 22 May 2002 ABI granted Kerburn Rose Capital Limited warrants to subscribe for 378,750 shares of common stock in the capital of ABI at £1.36 pence per share at any time through to 22 May 2009. Charles Bunker is a majority shareholder and director of Kerburn Rose Capital Limited.

On the 1 February 2008 Charles Bunker was granted warrants to subscribe for 50,000 shares of common stock in the capital of ABI at 12.25 pence per share at any time through to 31 January 2013.

There are no further disclosures to be made in accordance with Schedule 2(g) of the AIM Rules. 

In addition, ABI also announces that David Wilbraham, non-executive Chairman of the Company, will be retiring from the Board of ABI with effect from today. David has been a non-executive Director of ABI since its flotation in 2002, and non-executive Chairman since 2003. 

Edward Mulhare, currently a non-executive Director of the Company, will immediately become non-executive Chairman. Edward has vast experience of company directorship in the USA, where ABI predominantly operates, having served on the Boards of fifteen companies including Aldila, Inc., Truck Components, Inc., PanAmerican Diamond Co., McGraw Industries, Inc., and American Silver Co. He served as the Chairman of the Board and Chief Executive Officer of Merrill Lynch Interfunding, Inc. which managed a $1.6 billion leveraged acquisition portfolio. In addition, he has served as Executive Vice President of Republic National Bank of New York and Vice President of Prudential Insurance Co.

Thomas A. Nicolette, President and Chief Executive Officer of ABI, said,

"We are delighted to welcome Charles Bunker to the Board. We look forward to benefitting from his extensive financial experience in the UK where the Company is seeking to increase its product penetration over the coming months and years.

I would also like to take this opportunity, on behalf of the entire Board, to thank David Wilbraham for his tremendous contribution to the development of the Company and wish him well in retirement."

For further information please contact:

Thomas A. Nicolette

President & CEO

Tel. +1 856 848 8698

Alasdair Younie

Arbuthnot Securities Limited

Tel. +44 (0)20 7012 2139

Ben Simons or Eleanor Williamson

M: Communications

Tel. +44 (0) 20 7153 1540

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOABZLFLVBBBFBB
Date   Source Headline
6th Mar 20197:00 amRNSResult of Special Meeting of Shareholders
6th Feb 20199:00 amRNSHolding in Company
6th Feb 20197:01 amRNSForm DEFA14A Filing - Additional Proxy Materials
6th Feb 20197:00 amRNSNotice of Special Meeting of Shareholders
5th Feb 20191:00 pmRNSFurther Re. Directorate Change
28th Jan 20197:00 amRNSForm PRE 14A Filing
28th Dec 20183:45 pmRNSDirector/PDMR Shareholding
19th Dec 20184:45 pmRNSIntention to Delist from AIM
18th Dec 20186:00 pmRNSIssue of Equity
10th Dec 20187:00 amRNSResult of AGM & Form 8-K Filing
26th Nov 20182:00 pmRNSFurther Re. Notice of AGM
19th Nov 20182:00 pmRNSFurther Re. Strategic Update
16th Nov 20184:00 pmRNSReverse Stock Split Update
15th Nov 20187:00 amRNSNotice of AGM
15th Nov 20187:00 amRNS3rd Quarter 2018 Results
12th Nov 20187:00 amRNSForm 8-K Filing
8th Nov 20187:30 amRNSSuspension - Akers Biosciences, Inc.
8th Nov 20187:00 amRNSTemporary Suspension of Share Trading on LSE
7th Nov 20182:50 pmRNSStrategic Update & Reverse Stock Split
2nd Nov 20184:15 pmRNSIssue of Equity - Completion & Form 8-K/A Filing
2nd Nov 201810:52 amRNSUpdate Re Issue of Equity
31st Oct 20181:35 pmRNSIssue of Equity & Form 8-K
19th Oct 20182:53 pmRNSForm 8-K Filing
19th Oct 20187:00 amRNSDirectorate Change
12th Oct 20187:00 amRNSForm 8-K/A Filing & Other Updates
8th Oct 20187:00 amRNSDirectorate Change & Other Information
13th Sep 20187:00 amRNSDirectorate Change - Form 8-K Filing
15th Aug 20187:00 amRNS2nd Quarter & H1 2018 Results
27th Jul 20183:00 pmRNSHolding(s) in Company
26th Jul 20187:30 amRNSRestoration - Akers Biosciences Inc.
26th Jul 20187:00 amRNSMailing of 2017 Annual Report
20th Jul 20183:05 pmRNSIssue of Equity
20th Jul 20183:00 pmRNSCorrection: Issue of Equity
18th Jul 201812:00 pmRNSIndependent Sales Representative Agreements - PIFA
16th Jul 20187:03 amRNS1st Quarter 2018 Results
16th Jul 20187:02 amRNSFinal Results 2017 (Restated)
16th Jul 20187:01 amRNS3rd Quarter 2017 Results (Restated)
16th Jul 20187:00 amRNS2nd Quarter 2017 Results (Restated)
3rd Jul 201812:00 pmRNSIndependent Sales Representative Agreements - PIFA
2nd Jul 20187:30 amRNSSuspension - Akers Bioscience, Inc
29th Jun 20187:00 amRNSTemporary Suspension
21st Jun 20187:00 amRNSNotification of Class Action
20th Jun 20187:22 amRNSForm 8-K Filing
18th Jun 20187:00 amRNSForm 8-K Filing
6th Jun 20187:00 amRNSForm 8-K/A Filing
4th Jun 20187:00 amRNSForm 8-K Filing
31st May 20187:25 amRNSUpdate Re. Nasdaq Minimum Bid Price Requirement
29th May 20187:00 amRNSDirectorate Change
29th May 20187:00 amRNSWithdrawal of 510(k) Submission - Chlamydia Assay
29th May 20187:00 amRNSNotice of Form 10-Q Filing Delinquency from Nasdaq

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.